RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Drug-Induced Dyskinesia
Accession: DOID:9008394
browse the term
Definition: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
Synonyms: exact_synonym: Drug-Induced Dyskinesias; Medication Induced Dyskinesia; Medication-Induced Dyskinesias
primary_id: MESH:D004409
xref: EFO:1000904
GViewer not supported for the selected species.
G
Abat
4-aminobutyrate aminotransferase
ISO
RGD
PMID:6445277 PMID:7740056
RGD:10047091 RGD:1598524
NCBI chrNW_004624824:6,112,644...6,202,936
Ensembl chrNW_004624824:6,141,213...6,202,936
G
Cacna1d
calcium voltage-gated channel subunit alpha1 D
ISO
RGD
PMID:18947822
RGD:6906919
NCBI chrNW_004624822:3,391,045...3,734,258
Ensembl chrNW_004624822:3,392,044...3,919,415
G
Cat
catalase
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:19109989
NCBI chrNW_004624767:12,680,940...12,715,468
Ensembl chrNW_004624767:12,680,953...12,715,739
G
Cck
cholecystokinin
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:2320253
NCBI chrNW_004624730:77,310,080...77,314,258
Ensembl chrNW_004624730:77,309,633...77,314,384
G
Comt
catechol-O-methyltransferase
ISO
RGD
PMID:16437585
RGD:2289781
NCBI chrNW_004624747:569,127...588,479
Ensembl chrNW_004624747:581,832...588,333
G
Dbn1
drebrin 1
ISO
levodopainduced; protein:increased expression:striatum:
RGD
PMID:23241013
RGD:10398811
NCBI chrNW_004624733:12,616,537...12,631,967
Ensembl chrNW_004624733:12,616,423...12,632,133
G
Ddc
dopa decarboxylase
ISO
associated with Parkinson Disease; protein:decreased expression:striatum (rat)
RGD
PMID:20232137
RGD:5128860
NCBI chrNW_004624740:3,674,727...3,732,058
Ensembl chrNW_004624740:3,674,609...3,732,676
G
Drd1
dopamine receptor D1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:7845605 PMID:10858612 PMID:16982285 PMID:19520364
NCBI chrNW_004624733:14,517,540...14,522,173
Ensembl chrNW_004624733:14,518,146...14,520,905
G
Drd2
dopamine receptor D2
ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:7845605 PMID:10534246 PMID:14629710 PMID:18707801
RGD:2311579
NCBI chrNW_004624784:8,828,589...8,906,617
Ensembl chrNW_004624784:8,827,006...8,865,529
G
Drd3
dopamine receptor D3
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20945430
NCBI chrNW_004624731:34,318,733...34,369,111
Ensembl chrNW_004624731:34,319,130...34,363,184
G
Egr1
early growth response 1
ISO
RGD
PMID:22153973
RGD:10395307
NCBI chrNW_004624743:31,247,855...31,251,675
Ensembl chrNW_004624743:31,247,516...31,252,205
G
Fosb
FosB proto-oncogene, AP-1 transcription factor subunit
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17219962
NCBI chrNW_004624907:2,332,746...2,338,825
Ensembl chrNW_004624907:2,328,691...2,339,099
G
Gad1
glutamate decarboxylase 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:9767399
NCBI chrNW_004624787:8,308,759...8,345,929
Ensembl chrNW_004624787:8,308,759...8,347,686
G
Gch1
GTP cyclohydrolase 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chrNW_004624731:14,459,164...14,502,485
Ensembl chrNW_004624731:14,459,303...14,500,429
G
Gdnf
glial cell derived neurotrophic factor
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:11168568
NCBI chrNW_004624759:17,263,570...17,290,046
Ensembl chrNW_004624759:17,263,969...17,287,723
G
Glul
glutamate-ammonia ligase
ISO
RGD
PMID:6445277
RGD:10047091
NCBI chrNW_004624771:2,608,779...2,618,130
G
Grk6
G protein-coupled receptor kinase 6
ISO
associated with Parkinson Disease
RGD
PMID:20410529
RGD:5684919
NCBI chrNW_004624733:12,633,565...12,661,284
G
Gsk3b
glycogen synthase kinase 3 beta
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:26997328
RGD:13792768
NCBI chrNW_004624731:28,178,647...28,368,784
Ensembl chrNW_004624731:28,178,628...28,366,420
G
Homer1
homer scaffold protein 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:24126708
NCBI chrNW_004624869:3,878,646...4,012,211
Ensembl chrNW_004624869:3,880,001...4,012,240
G
Htr1a
5-hydroxytryptamine receptor 1A
ISO
RGD
PMID:21352823
RGD:5683628
NCBI chrNW_004624815:5,817,196...5,821,197
Ensembl chrNW_004624815:5,816,601...5,820,864
G
Mapt
microtubule associated protein tau
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:25511986
RGD:13800920
NCBI chrNW_004624849:2,320,887...2,421,099
G
Mtor
mechanistic target of rapamycin kinase
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:23938307
RGD:10040953
NCBI chrNW_004624818:1,570,155...1,698,264
Ensembl chrNW_004624818:1,570,276...1,698,259
G
Pdyn
prodynorphin
treatment severity
ISO
CTD Direct Evidence: marker/mechanism associated with Parkinsonism associated with Parkinsonism;protein:increased expression:striatum
CTD RGD
PMID:9767399 PMID:10869049 PMID:17884291 PMID:21737418
RGD:401850563 RGD:401851046 RGD:401900134
NCBI chrNW_004624741:3,239,101...3,253,507
Ensembl chrNW_004624741:3,237,942...3,253,503
G
Penk
proenkephalin
disease_progression treatment
ISO
mRNA:increased expression:brain:striatum: CTD Direct Evidence: marker/mechanism associated with Parkinsonism;mRNA:increased expression:striatum
RGD CTD
PMID:9767399 PMID:10869049 PMID:20456008 PMID:26113400
RGD:10003039 RGD:401851054 RGD:401900134
NCBI chrNW_004624886:3,595,485...3,613,117
Ensembl chrNW_004624886:3,595,450...3,613,593
G
Ppp1r1b
protein phosphatase 1 regulatory inhibitor subunit 1B
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:27771532
RGD:13514053
NCBI chrNW_004624795:3,432,179...3,439,490
Ensembl chrNW_004624795:3,431,689...3,439,545
G
Rasgrf1
Ras protein specific guanine nucleotide releasing factor 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:21115823
NCBI chrNW_004624941:110,752...222,143
Ensembl chrNW_004624941:110,676...222,092
G
Rela
RELA proto-oncogene, NF-kB subunit
ISO
protein:increased expression:nucleus, brain
RGD
PMID:18590723
RGD:2298778
NCBI chrNW_004624767:20,732,813...20,742,016
Ensembl chrNW_004624767:20,732,938...20,741,272
G
Rgs4
regulator of G protein signaling 4
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:24969021
RGD:13524515
NCBI chrNW_004624826:1,570,143...1,577,300
Ensembl chrNW_004624826:1,569,854...1,579,627
G
Rgs9
regulator of G protein signaling 9
ISO
CTD Direct Evidence: marker/mechanism|therapeutic
CTD
PMID:18160641 PMID:24663062
NCBI chrNW_004624870:3,138,311...3,249,297
Ensembl chrNW_004624870:3,143,950...3,218,117
G
Th
tyrosine hydroxylase
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chrNW_004624767:15,003,073...15,010,207
Ensembl chrNW_004624767:15,003,092...15,010,154
G
Drd3
dopamine receptor D3
ISO
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chrNW_004624731:34,318,733...34,369,111
Ensembl chrNW_004624731:34,319,130...34,363,184
G
Sod2
superoxide dismutase 2
ISO
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chrNW_004624855:3,260,800...3,271,864
Ensembl chrNW_004624855:3,260,809...3,271,367
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all